To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Biodesix Closes Series D Financing
Read time: Less than a minute
The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). Funding will also support clinical validation studies, product development, and ongoing collaborations with a number of biotechnology and pharmaceutical companies.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
